Our new corporate presentation is now available to download. Listen to the video update from CEO, Nigel Theobald here. 

Key points covered in the presentation include:

  • N4 Pharma’s strategic focus on two key lead programs: N4 101 for Irritable Bowel Disease (IBD) and ECP 105 for post-surgical scarring prevention
  • N4 Pharma’s proprietary delivery technologies, Nuvec® and LipTide™
  • The Company’s aim to advance preclinical studies and prepare for CTA/IND filings in the coming years, while also pursuing licensing and platform collaboration opportunities.